Developmental pharmacology: A moving target

Area of Science:

• Developmental pharmacology
• Pediatric drug safety
• Clinical pharmacology

Background:

• Limited availability of drugs with confirmed efficacy and safety data for pediatric and neonatal populations.
• Children's unique physiological, psychological, and developmental differences impact drug potency, efficacy, and toxicity compared to adults.
• Current pediatric pharmacotherapy faces challenges due to insufficient data on drug behavior in developing individuals.

Purpose of the Study:

• To highlight key issues in contemporary developmental pharmacology.
• To emphasize the critical role of age and development in pediatric drug pharmacokinetics (PK) and pharmacodynamics (PD).
• To underscore the necessity of integrating developmental pharmacology into pediatric drug development programs.

Main Methods:

• Review of existing literature on pediatric drug pharmacokinetics (PK) and pharmacodynamics (PD).
• Analysis of clinical and animal data on receptor ontogeny and drug response.
• Focus on the impact of physiological characteristics and clinical trial data in children.

Main Results:

• Child's age and development significantly influence drug PK processes.
• Pharmacodynamic (PD) data is less understood than PK, but receptor ontogeny shows developmental changes in drug response independent of PK.
• Absence of comprehensive PK/PD data increases the risk of medication errors and treatment failure in children.

Conclusions:

• Understanding growth and development is essential for effective pediatric drug development.
• Accurate drug dosing in children must consider physiological characteristics and PK/PD parameters derived from pediatric clinical trials.
• Integrating developmental pharmacology knowledge is crucial to improve the safety and efficacy of medicines for children.